1297 related articles for article (PubMed ID: 33427873)
1. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
2. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
3. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
4. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
[TBL] [Abstract][Full Text] [Related]
5. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
Rauchmann BS; Schneider-Axmann T; Perneczky R;
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
[TBL] [Abstract][Full Text] [Related]
6. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
[TBL] [Abstract][Full Text] [Related]
8. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
[TBL] [Abstract][Full Text] [Related]
9. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Andreasson U; Zetterberg H; Blennow K;
JAMA Neurol; 2017 May; 74(5):557-566. PubMed ID: 28346578
[TBL] [Abstract][Full Text] [Related]
10. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
12. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
13. Future perspective and clinical applicability of the combined use of plasma phosphorylated tau 181 and neurofilament light chain in Subjective Cognitive Decline and Mild Cognitive Impairment.
Giacomucci G; Mazzeo S; Ingannato A; Crucitti C; Bagnoli S; Padiglioni S; Romano L; Galdo G; Emiliani F; Frigerio D; Ferrari C; Moschini V; Morinelli C; Notarelli A; Sorbi S; Nacmias B; Bessi V
Sci Rep; 2024 May; 14(1):11307. PubMed ID: 38760423
[TBL] [Abstract][Full Text] [Related]
14. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
[TBL] [Abstract][Full Text] [Related]
15. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.
Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL;
Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
17. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
Sarto J; Ruiz-García R; Guillén N; Ramos-Campoy Ó; Falgàs N; Esteller D; Contador J; Fernández G; González Y; Tort-Merino A; Juncà-Parella J; Bosch B; Borrego-Écija S; Molina-Porcel L; Castellví M; Vergara M; Antonell A; Augé JM; Naranjo L; Sanchez-Valle R; Lladó A; Balasa M
Neurology; 2023 Feb; 100(8):e860-e873. PubMed ID: 36450604
[TBL] [Abstract][Full Text] [Related]
19. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
20. Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Zetterberg H; Abramowicz M; Scheffler M; Assal F; Garibotto V; Blennow K; Frisoni GB
Alzheimers Res Ther; 2024 May; 16(1):110. PubMed ID: 38755703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
